Introduction/Aims There is less written about failure patterns after prostate brachytherapy (BT) alone or in combination with external beam radiotherapy.

Slides:



Advertisements
Similar presentations
Impact of cytokeratin-positive cells in bone marrow on survival in patients with non-metastatic prostate cancer treated by radiotherapy PURPOSE To evaluate.
Advertisements

Pulmonary Stereotactic Ablative Radiotherapy:
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Management of locally advanced & metastatic prostate cancer Dr. Purvish. M. Parikh MD, DNB, PhD, FICP Professor & Head Department of Medical Oncology Tata.
Radiation Therapy in Prostate Cancer Current Status and New Advances Mahdi Aghili MD,AFSA Cancer Institute -Department of Radiation Oncology Associated.
H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
Steven Joniau Filip Ameye
Prostate Radiotherapy A-Z
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
 These slides were extracted from a larger set of comprising a presentation entitled “Comparing Treatment Results of PROSTATE CANCER” dated 15_01_2013(3).
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
Radiotherapy - the art of the invisible Terry Kehoe Consultant Clinical Scientist Head of Oncology Physics Edinburgh Cancer Centre “How to crack a walnut”
Association Radiothérapie-Hormonothérapie Cancers localisés et localement avancés de la prostate Michel Bolla, Camille Verry Clinique Universitaire de.
Conclusions HDR brachytherapy boost combined with moderate dose external beam irradiation resulted in a very high local control rate and few recurrences.
Comparison of Outcomes between Brachytherapy and Intensity Modulated Radiotherapy in High Risk Prostate Cancer M. A. Weller, C. A. Reddy, J. Kittel, K.
7 th July CRH talk Dr George Hruby Senior Staff Specialist Sydney Cancer Centre.
Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.
Quantitative Dosimetric Analysis Of Patterns Of Local Relapse After IMRT For Primary Extremity Soft Tissue Sarcomas Ryan M. Lanning, Sean L. Berry, Michael.
Updated 5-year Biochemical Relapse-Free Survival after Prostate Brachytherapy Jenny P. Nobes St. Luke’s Cancer Centre, The Royal Surrey County Hospital,
Radiologic Assessment of the Genitourinary Diaphragm Using MRI with Endorectal Coil in Men with Localized Prostate Cancer ASTRO Annual Meeting 2014, #3792.
Ten Year Outcomes In Men Under 60 Treated With Iodine-125 Permanent Brachytherapy As Monotherapy GU - Prostate Cancer: Novel Imaging (MRI,PET) & Brachytherapy.
PROSTATE CANCER: RADIATION APPROACHES for advanced disease
PROSTATE CANCER: RADIATION THERAPY APPROACHES ANDREW L. SALNER, MD FACR DIRECTOR HELEN & HARRY GRAY CANCER CENTER HARTFORD HOSPITAL, CT.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
A prospective randomized trial
Long-Term versus Short-Term Androgen Deprivation Combined with High-Dose Radiotherapy for Intermediate and High Risk Prostate Cancer: Preliminary Results.
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Hormone treatment combined with radiotherapy
High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.
Adjuvant treatment for endometrial cancer Ameri A Associate Professor of Radiation Oncology Shahid Beheshti University of Medical Sciences Dec Pars.
PATTERNS OF CARE OF PATIENTS WITH AN OCCULT LOCOREGIONAL RELAPSE ON CHOLINE PET/CT AFTER A PRIOR CURATIVE TREATMENT FOR LOCALIZED PROSTATE CANCER Choline.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
David Spellberg, M.D., FACS Naples Urology Associates, P.A.
Patient and Tumour Characteristics Median age 60 years (26-92) Karnofsky Status:median 90 (50-100) Histology:SCC: n=120 (83%) Tumor size: ≥ 5 cm: n=78.
Image Guided Interstitial Brachytherapy For Locally Advanced Gynaecological Cancer With A MUPIT Applicator M.A.D. Haverkort, MD 1, E. Van der Steen - Banasik,
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Dose Calculations for Cyberknife Stereotactic Body Radiation Therapy For CK, one can fractionate the therapy yet remain convenient and non-invasive for.
Modern Radiation Oncology
Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.
Radiation therapy for Early Stage Prostate Cancer
Bladder Cancer and Prostatic Cancer
Prostate cancer นพ.ชัชชัย หอมเกตุ.
MINIMALLY INVASIVE URO-ONCOLOGICAL TREATMENTS ON THE AMBULATORY SETTING PROSTATE BRACHYTHERAPY I125 Luís Campos Pinheiro.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
Relationship between the site of esophageal carcinoma and survival of patients with locally advanced disease Authors: Andrea Masarykova, Ingrid Zavacka,
Figure 1. The (a) anterior–posterior and (b) right-lateral fields and (c, d) the isodose distributions of two axial planes in one patient with T2 stage.
RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.
Evaluation of biologically equivalent dose escalation, clinical outcome, and toxicity in prostate cancer radiotherapy: A meta-analysis of 12,000 patients.
The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients 
Prostate Cancer: Highlights from 2006
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Apollo Gleneagles Hospitals,
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
Volume 72, Issue 5, Pages (November 2017)
Evaluation of adherence to quality measures for prostate cancer radiotherapy in the United States: Results from the Quality Research in Radiation Oncology.
What is New in Hormone Therapy for Prostate Cancer in 2007?
Volume 67, Issue 6, Pages (June 2015)
Volume 64, Issue 6, Pages (December 2013)
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Jacques Irani  European Urology Supplements 
Figure 2 The evolution of brachytherapy for prostate cancer
Volume 53, Issue 6, Pages (June 2008)
Management of Prostate Cancer: Global Strategies
Figure 3 Target volume definitions
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Presentation transcript:

Introduction/Aims There is less written about failure patterns after prostate brachytherapy (BT) alone or in combination with external beam radiotherapy (EBRT) for localized prostate cancer. To analyze patterns of failure following biochemical failure for prostate cancer patients treated with I-125 BT with or without supplemental EBRT (not to pelvis) with or without neoadjuvant androgen deprivative therapy (NADT). #1240 Patterns of Failure Following Biochemical Failure in 1311 Prostate Cancer Patients Treated with Brachytherapy with/without External Beam Radiation Therapy A. Yorozu, S. Saito, K. Toya, Y. Shiraishi, N. Kuroiwa, A. Takahashi, Y. Yagi, T. Nishiyama, T. Tanaka, Y. Shinya, Dept. of Radiation Oncology & Urology, Tokyo Medical Center, National Hospital Organization, Tokyo, Japan

Patients & Methods 1311 men with prostate cancer received I-125 BT from 2003 to We analyzed patterns of failure comprehensively, including 83 men with definitive biochemical failure according to Phoenix definition. Risk groups according to the NCCN guidelines; – Low-risk; 460, Intermediate-risk; 704, High-risk; % of men received supplemental EBRT to the prostate & seminal vesicles: 40% received NADT (median 8 months). Local failure was defined as a positive post-treatment biopsy (95%) and/or imaging consistent with failure in the prostate or seminal vesicles. First failure site was defined as the earliest anatomic relapse site. Anatomic relapse patterns were classified as a local, pelvic nodal, and distant pattern. The pattern was unable to be determined in 4 (5%).

Results: Failure patterns according to risk group Local failure High risk 3.9% at 7-yr Intermediate risk 1.7% Low risk 1.3% P=0.031 Nodal failure High risk 6.8% Intermediate risk 1.1% Low risk 0.0% P=0.009 Distant failure High risk 8.6% Intermediate risk 3.8% Low risk 1.0% P<0.001 LocalNodalDistant BED*Risk group NADTT stage NADT Predictive factors for failure patterns on multivariate analysis BED*: biologically effective dose (α/β=2Gy)

Conclusions Local failure BED <180 Gy2 4.8% at 7 yr BED ≥180 Gy2 1.2% p=0.002